hat
Ceritinib (Non komès Zykadia) se yon dwòg pou tretman yon kalite espesifik kansè nan poumon. [1] Li se yon inhibitor lymphoma lenfom anaklastik (ALK). Li te apwouve nan mwa avril 2014 pa Administrasyon Manje ak Dwòg pou tretman ALK pozitif metastatik ki pa ti selil kansè nan poumon (NSCLC) apre tretman ak krizotinib.
eng
Ceritinib (trade name Zykadia) is a drug for the treatment of a specific type of lung cancer.[1] It is an anaplastic lymphoma kinase (ALK) inhibitor.It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.